Фармсинтез logo
Фармсинтез LIFE

Фармсинтез Financial Statements 2007-2026 | LIFE

Key Metrics Фармсинтез

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007

Operating Cash Flow Per Share

-0.011 -0.208 -0.773 -0.321 -0.054 -0.498 -3.81 -1.34 -5.89 -3.27 -1.65 0.178 - - - -

Free Cash Flow Per Share

-0.023 -0.209 -0.805 -0.369 -0.12 -0.586 -4.03 -1.44 -6.46 -4.43 -2.67 -0.095 -0.046 -0.04 -0.03 -

Cash Per Share

0.031 0.045 0.035 0.246 0.051 1.37 3.02 2.03 1.25 5.16 1.08 1.15 1.55 0.18 0.031 0.049

Price To Sales Ratio

3.33 3.85 5.55 4.29 5.75 4.58 3.79 4.95 4.8 7.48 3.08 14.8 25.4 13.1 16.6 17.4

Dividend Yield

- - - - - - - - - - - - - - - -

Payout Ratio

- - - - - - - - - - - - - - - -

Revenue Per Share

1.26 1.46 1.23 0.967 0.974 2.62 4.36 2.18 2.65 2.27 3.77 1.37 0.915 1.83 1.44 1.38

Net Income Per Share

-0.69 -2.32 -1.74 -6.02 0.207 -9.13 -5.92 -2.34 -1.43 -1.37 -0.771 0.047 0.063 0.112 0.017 0.135

Book Value Per Share

0.403 1.15 3.37 13.9 16.9 6.46 32.9 14 16.2 16 9.85 2.75 0.962 2.17 2.13 2.11

Tangible Book Value Per Share

-0.701 -0.183 1.98 12.6 15.5 2.59 24.8 11.8 13.9 12.9 8.94 1.68 0.955 2.15 2.11 2.09

Shareholders Equity Per Share

0.403 1.15 3.37 13.9 16.9 6.37 30.3 14 16.2 16 9.85 2.75 0.962 2.17 2.13 2.11

Interest Debt Per Share

2.62 2.47 2.17 0.544 0.1 0.858 1.5 1.96 0.256 3.24 0.667 0.03 0.004 0.199 0.214 0.065

Market Cap

1.26 B 1.69 B 2.06 B 1.25 B 1.62 B 3.31 B 2.5 B 1.64 B 1.81 B 1.83 B 820 M 6.09 B 7 B 3 B 3 B 3 B

Enterprise Value

2 B 2.38 B 2.68 B 1.35 B 1.64 B 3.22 B 2.36 B 1.93 B 1.74 B 1.68 B 794 M 6.1 B 6.99 B 2.99 B 3.02 B 3 B

P/E Ratio

-6.09 -2.42 -3.93 -0.689 27.1 -1.31 -2.79 -4.62 -8.85 -12.4 -15 435 367 213 1.41 K 178

P/OCF Ratio

-377 -26.9 -8.86 -12.9 -105 -24.1 -4.34 -8.04 -2.16 -5.19 -7.05 114 - - - -

P/FCF Ratio

-185 -26.8 -8.5 -11.2 -46.5 -20.5 -4.1 -7.5 -1.97 -3.84 -4.35 -212 -504 -599 -792 -

P/B Ratio

10.4 4.89 2.03 0.298 0.332 1.88 0.544 0.769 0.783 1.06 1.18 7.37 24.2 11.1 11.3 11.4

EV/Sales

5.27 5.43 7.2 4.63 5.83 4.45 3.56 5.81 4.6 6.84 2.98 14.8 25.4 13.1 16.8 17.4

EV/EBITDA

-14.3 -3.68 -13.4 -7.03 -7.69 -3.2 -3.84 -5.29 -10.8 -14.1 -26.4 197 250 323 416 120

EV/OCF

-596 -38 -11.5 -14 -106 -23.4 -4.08 -9.46 -2.06 -4.75 -6.82 114 - - - -

Earnings Yield

-0.164 -0.413 -0.255 -1.45 0.037 -0.761 -0.359 -0.217 -0.113 -0.08 -0.066 0.002 0.003 0.005 0.001 0.006

Free Cash Flow Yield

-0.005 -0.037 -0.118 -0.089 -0.022 -0.049 -0.244 -0.133 -0.509 -0.261 -0.23 -0.005 -0.002 -0.002 -0.001 -

Debt To Equity

6.16 2.05 0.615 0.039 0.005 0.132 0.049 0.139 0.015 0.202 0.061 0.007 0.0 0.08 0.094 0.03

Debt To Assets

0.557 0.497 0.304 0.028 0.004 0.069 0.037 0.103 0.014 0.161 0.048 0.006 0.0 0.058 0.065 0.021

Net Debt To EBITDA

-5.26 -1.07 -3.08 -0.518 -0.108 0.094 0.24 -0.79 0.478 1.32 0.88 0.097 -0.412 -0.029 2.97 0.075

Current Ratio

0.169 0.208 0.454 0.266 0.384 0.974 1.8 1.92 5.32 2.55 2.01 3.67 1.13 1.49 1.37 1.21

Interest Coverage

-4.05 -4.65 -1.4 - 11.5 -634 -195 -279 -98.3 -96.7 -37.6 1 33.1 5.4 12.8 233

Income Quality

0.016 0.085 0.441 0.053 -0.259 0.048 0.611 0.512 4.23 2.3 2.13 -7.57 - - - -

Sales General And Administrative To Revenue

0.052 0.077 0.065 0.543 0.055 0.422 0.209 0.153 0.15 0.168 - - 0.121 0.138 0.167 0.134

Intangibles To Total Assets

0.248 0.281 0.204 0.069 0.063 0.317 0.199 0.118 0.132 0.152 0.073 0.316 0.002 0.006 0.007 0.007

Capex To Operating Cash Flow

-1.04 -0.004 -0.042 -0.15 -1.25 -0.177 -0.058 -0.072 -0.097 -0.354 -0.622 1.54 - - - -

Capex To Revenue

0.009 0.001 0.026 0.05 0.069 0.034 0.051 0.044 0.215 0.51 0.271 0.2 0.05 0.022 0.021 -

Capex To Depreciation

0.126 0.009 0.218 0.559 0.355 0.479 0.482 0.46 2.24 5.47 2.65 3.45 - - - -

Stock Based Compensation To Revenue

- - - - - - - - - - - - - - - -

Graham Number

2.5 7.73 11.5 43.4 8.86 36.2 63.5 27.2 22.9 22.1 13.1 1.7 1.17 2.34 0.903 2.53

Return On Invested Capital, ROIC

-0.192 -0.153 -0.025 -0.477 0.423 -1.16 -0.11 -0.22 -0.091 -0.083 -0.216 0.002 0.101 0.126 0.027 0.081

Return On Tangible Assets, ROTA

-0.206 -0.681 -0.321 -0.331 0.01 -1.1 -0.183 -0.14 -0.093 -0.08 -0.067 0.02 0.021 0.038 0.006 0.045

Graham Net Net

-3.95 -3.48 -3.3 -5.1 -5.09 -2.8 -1 -0.015 0.202 2.53 0.507 0.633 -0.347 -0.393 -0.658 -0.626

Working Capital

-977 M -787 M -560 M -1.09 B -811 M -30.2 M 768 M 677 M 959 M 675 M 187 M 470 M 76.5 M 51.3 M 43 M 23.3 M

Tangible Asset Value

-211 M -55.2 M 596 M 3.78 B 4.47 B 715 M 3.76 B 1.79 B 1.98 B 1.39 B 632 M 507 M 287 M 268 M 263 M 261 M

Net Current Asset Value, NCAV

-1.02 B -874 M -573 M -1.29 B -1.12 B -477 M 590 M 675 M 953 M 671 M 186 M 459 M 73.1 M 50.7 M 38.9 M 21.6 M

Invested Capital

-300 M -59.9 M 210 M -366 M -72.1 M 1.45 B 2.39 B 1.45 B 1.76 B 1.41 B 588 M 838 M 271 M 248 M 253 M 249 M

Average Receivables

- - - - 222 M 517 M 507 M 212 M 78 M 154 M 76.1 M - - - - -

Average Payables

160 M 160 M 210 M 379 M 481 M 2.68 B 2.54 B 154 M 90.8 M 91.6 M 65.2 M 32.1 M 68.8 M 78.9 M 91.5 M -

Average Inventory

39.1 M 52.9 M 111 M 212 M 238 M 189 M 198 M 190 M 117 M 71.5 M 64.6 M 71 M 71.7 M 67.3 M 62.1 M -

Days Sales Outstanding

- - - - - 224 326 466 - 232 209 - - - - -

Days Payables Outstanding

218 186 306 336 753 392 6.61 K 390 285 125 323 - 138 173 308 385

Days Of Inventory On Hand

51.2 47.6 120 213 393 182 230 489 344 186 159 80.4 166 157 248 219

Receivables Turnover

- - - - - 1.63 1.12 0.783 - 1.57 1.75 - - - - -

Payables Turnover

1.67 1.96 1.19 1.09 0.485 0.932 0.055 0.936 1.28 2.93 1.13 - 2.64 2.11 1.19 0.949

Inventory Turnover

7.12 7.66 3.04 1.71 0.929 2.01 1.58 0.746 1.06 1.97 2.29 4.54 2.2 2.32 1.47 1.66

Return On Equity, ROE

-1.71 -2.02 -0.518 -0.433 0.012 -1.43 -0.195 -0.167 -0.088 -0.086 -0.078 0.017 0.066 0.052 0.008 0.064

Capex Per Share

0.012 0.001 0.032 0.048 0.067 0.088 0.221 0.096 0.569 1.16 1.02 0.273 0.046 0.04 0.03 -

All numbers in RUB currency

Quarterly Key Metrics Фармсинтез

2023-Q2 2022-Q4 2022-Q2 2021-Q4 2021-Q2 2020-Q4 2020-Q2 2019-Q4 2019-Q2 2018-Q4 2018-Q2 2017-Q4 2017-Q2 2016-Q4 2016-Q2 2015-Q4 2015-Q2 2014-Q4 2014-Q2 2013-Q4 2013-Q2 2012-Q4 2011-Q4 2011-Q2 2010-Q4 2010-Q2 2009-Q4 2009-Q2 2008-Q4 2008-Q2

Operating Cash Flow Per Share

-0.001 0.0 -0.0 -0.118 -0.09 -0.469 -0.308 -0.082 -0.144 -0.0 -0.0 0.0 -0.0 -0.003 0.0 -0.001 -0.0 -0.003 -0.003 -1.43 -1.91 -1.25 0.089 0.089 - - - - - -

Free Cash Flow Per Share

-0.001 0.0 -0.0 -0.119 -0.091 -0.489 -0.32 -0.132 -0.144 -0.0 -0.0 0.0 -0.0 -0.003 0.0 -0.001 -0.0 -0.003 -0.003 -1.94 -2.58 -1.69 -0.048 -0.048 -0.023 -0.023 -0.02 -0.02 -0.008 -0.015

Cash Per Share

0.848 0.145 0.003 0.045 0.04 0.035 0.06 0.231 0.043 0.016 0.837 1.51 0.297 3.02 0.818 2.27 1.49 1.25 2.99 4.52 9.62 1.08 1.15 1.35 1.55 0.812 0.18 0.106 - 0.04

Price To Sales Ratio

13.2 7.22 5.86 7.8 8.41 8.99 13.8 12.8 8.46 6.71 21.1 7.92 10.8 5.35 12.6 13.2 7.75 9.6 10.5 8.08 38.1 6.16 29.6 34 50.8 52.5 26.2 26.2 34.7 33.3

Dividend Yield

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Payout Ratio

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue Per Share

0.569 0.582 0.691 0.719 0.737 0.762 0.477 0.325 0.631 0.835 0.345 1.51 1.14 3.08 1.27 0.818 1.63 1.32 1.32 2.1 0.506 1.88 0.684 0.684 0.457 0.457 0.915 0.915 0.691 0.721

Net Income Per Share

-0.54 -0.475 -0.224 -1.48 -0.839 -1.39 -0.361 -6.1 -0.13 -0.107 -1.28 -4.05 -5 -7.6 3.38 -0.472 -1.87 -0.717 -0.717 1.26 -1.64 -0.386 0.023 0.023 0.032 0.032 0.056 0.056 0.068 0.009

Book Value Per Share

2.1 0.41 1.15 1.15 2.48 3.37 4.67 4.7 14.5 11.8 4.48 7.1 8.49 32.8 16.9 14 13.2 16.2 13 14 16.1 9.85 2.75 1.85 0.962 0.93 2.17 2.15 - 2.12

Tangible Book Value Per Share

0.801 -0.929 -0.17 -0.183 1.2 2.21 3.47 3.46 13.3 10.5 0.878 2.85 7.38 24.8 14.7 11.8 11 13.9 12.8 11.3 15.2 8.94 1.68 1.32 0.955 0.923 2.15 2.13 - 2.1

Shareholders Equity Per Share

2.1 0.41 1.15 1.15 2.48 3.37 4.67 4.7 14.5 11.8 4.48 7.01 8.49 30.3 16.9 14 13.2 16.2 13 14 16.1 9.85 2.75 1.85 0.962 0.93 2.17 2.15 - 2.12

Interest Debt Per Share

2.51 2.53 2.06 2.35 1.44 1.34 0.922 0.878 0.115 1.14 0.986 0.925 1.97 1.48 3.91 1.94 0.14 0.249 0.254 2.82 0.819 0.633 0.025 0.015 0.002 0.038 0.186 0.2 - 0.139

Market Cap

2.28 B 1.24 B 1.22 B 1.69 B 1.87 B 2.06 B 1.96 B 1.2 B 1.67 B 1.64 B 2.2 B 3.01 B 3.69 B 2.51 B 2.43 B 1.64 B 1.91 B 1.81 B 1.98 B 2.1 B 1.78 B 820 M 6.09 B 7.01 B 7 B 7.22 B 3 B 3 B 3 B 3 B

Enterprise Value

2.79 B 1.98 B 1.82 B 2.38 B 2.29 B 2.45 B 2.22 B 1.39 B 1.7 B 1.97 B 2.29 B 2.92 B 4.28 B 2.36 B 3.02 B 1.93 B 1.92 B 1.74 B 1.62 B 1.94 B 967 M 794 M 6.1 B 7 B 6.99 B 7.22 B 2.99 B 3.01 B - 3.01 B

P/E Ratio

-3.49 -2.21 -4.52 -0.948 -1.85 -1.24 -4.56 -0.17 -10.3 -13.1 -1.43 -0.741 -0.612 -0.543 1.19 -5.72 -1.69 -4.43 -4.82 3.38 -2.94 -7.52 218 250 184 189 107 107 88.8 705

P/OCF Ratio

-6.61 K 63 K -53 K -47.6 -68.6 -14.6 -21.4 -50.3 -37 -21.4 K -61.5 K 338 K -25.2 K -5.78 K 59.8 K -10.4 K -42.2 K -4 K -5.09 K -11.9 -10.1 -9.28 228 262 - - - - - -

P/FCF Ratio

-6 K 68.7 K -49.1 K -47.3 -68.4 -14 -20.6 -31.3 -37 -22.7 K -36.8 K 1.25 M -24.7 K -5.65 K 62.2 K -9.59 K -40.7 K -3.66 K -4.62 K -8.77 -7.45 -6.86 -424 -488 -1.01 K -1.04 K -1.2 K -1.2 K -3.17 K -1.58 K

P/B Ratio

3.59 10.2 3.54 4.89 2.5 2.03 1.41 0.883 0.368 0.473 1.63 1.71 1.44 0.545 0.952 0.771 0.961 0.783 1.07 1.22 1.2 1.18 7.37 12.6 24.2 25.8 11.1 11.2 - 11.3

EV/Sales

16.2 11.5 8.75 11 10.3 10.7 15.6 14.8 8.64 8.05 22 7.67 12.5 5.04 15.7 15.5 7.79 9.19 8.6 7.47 20.7 5.96 29.6 34 50.8 52.4 26.2 26.3 - 33.4

EV/EBITDA

-72.6 -33.3 -487 -5.39 -10 -8 -24.6 -8.72 -53 2.51 -2.27 -1.12 -4.9 -0.902 -11.3 -7.63 -7.26 -21.6 -20.2 -16.8 -42.6 -52.9 393 452 499 515 647 649 - 830

EV/OCF

-8.07 K 100 K -79 K -67.1 -84.1 -17.4 -24.2 -58.2 -37.8 -25.7 K -63.8 K 328 K -29.2 K -5.44 K 74.2 K -12.2 K -42.4 K -3.84 K -4.18 K -11 -5.48 -8.99 228 262 - - - - - -

Earnings Yield

-0.072 -0.113 -0.055 -0.264 -0.135 -0.202 -0.055 -1.47 -0.024 -0.019 -0.175 -0.337 -0.408 -0.461 0.211 -0.044 -0.148 -0.056 -0.052 0.074 -0.085 -0.033 0.001 0.001 0.001 0.001 0.002 0.002 0.003 0.0

Free Cash Flow Yield

-0.0 0.0 -0.0 -0.021 -0.015 -0.071 -0.049 -0.032 -0.027 -0.0 -0.0 0.0 -0.0 -0.0 0.0 -0.0 -0.0 -0.0 -0.0 -0.114 -0.134 -0.146 -0.002 -0.002 -0.001 -0.001 -0.001 -0.001 -0.0 -0.001

Debt To Equity

1.2 6.16 1.75 2.05 0.578 0.396 0.198 0.187 0.008 0.096 0.22 0.132 0.232 0.049 0.232 0.139 0.011 0.015 0.019 0.202 0.051 0.061 0.007 0.005 0.0 0.039 0.08 0.087 - 0.062

Debt To Assets

0.444 0.557 0.446 0.497 0.232 0.196 0.111 0.105 0.006 0.073 0.095 0.069 0.164 0.037 0.164 0.103 0.009 0.014 0.017 0.161 0.039 0.048 0.006 0.003 0.0 0.017 0.058 0.061 - 0.043

Net Debt To EBITDA

-13.1 -12.4 -161 -1.57 -1.84 -1.28 -2.85 -1.18 -1.12 0.418 -0.084 0.036 -0.672 0.056 -2.2 -1.14 -0.033 0.956 4.39 1.36 35.8 1.76 0.194 -0.276 -0.825 -0.422 -0.058 2.3 - 3.23

Current Ratio

0.542 0.169 0.25 0.208 0.303 0.454 0.516 0.505 0.266 0.578 0.695 0.974 1.16 1.8 1.16 1.92 3.74 5.32 7.35 2.55 2.9 2.01 3.67 1.7 1.13 1.18 1.49 1.43 - 1.29

Interest Coverage

- - -3.45 - - - - - - - - - - - - - - -98.3 -98.3 - - -37.6 1 1 33.1 33.1 5.4 5.4 233 12.8

Income Quality

2.11 -0.14 0.341 0.08 0.108 0.338 0.852 0.014 1.11 2.44 0.093 -0.009 0.097 0.376 0.079 2.21 0.16 3.6 4.91 -1.14 K 5.95 2.3 -7.57 -7.57 - - - - - -

Sales General And Administrative To Revenue

0.525 0.405 0.202 0.193 0.197 0.201 0.274 0.587 0.522 0.48 1.02 0.638 0.965 0.579 0.349 0.625 0.344 0.15 0.15 0.408 0.458 - - - 0.121 0.121 0.138 0.138 0.134 0.167

Intangibles To Total Assets

0.23 0.295 0.293 0.281 0.207 0.17 0.144 0.148 0.063 0.084 0.348 0.317 0.092 0.199 0.092 0.118 0.144 0.132 0.009 0.152 0.042 0.073 0.316 0.168 0.002 0.004 0.006 0.007 - 0.007

Capex To Operating Cash Flow

-0.101 0.083 -0.08 -0.006 -0.003 -0.043 -0.039 -0.606 - -0.06 -0.668 0.729 -0.02 -0.022 0.04 -0.082 -0.036 -0.093 -0.101 -0.354 -0.354 -0.354 1.54 1.54 - - - - - -

Capex To Revenue

0.0 0.0 0.0 0.001 0.0 0.027 0.025 0.154 - 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.241 1.34 0.235 0.2 0.2 0.05 0.05 0.022 0.022 0.011 0.021

Capex To Depreciation

2.86 0.104 0.157 0.013 0.004 0.231 0.199 34.6 - 0.17 0.868 0.299 0.102 0.276 0.043 0.837 0.102 1.73 3.27 5.23 5.23 5.23 3.45 3.45 - - - - - -

Stock Based Compensation To Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Graham Number

5.05 2.09 2.4 6.18 6.84 10.3 6.16 25.4 6.52 5.34 11.4 25.3 30.9 72 35.8 12.2 23.5 16.2 14.5 19.9 24.3 9.24 1.2 0.985 0.828 0.814 1.66 1.65 - 0.637

Return On Invested Capital, ROIC

-0.103 -0.089 -0.114 -0.105 -0.168 -0.061 -0.03 -1.13 -0.04 0.02 -0.149 -0.236 -0.15 -0.242 0.22 -0.155 -0.141 -0.046 -0.057 -0.065 -0.019 -0.108 0.001 0.001 0.05 0.05 0.063 0.063 - 0.014

Return On Tangible Assets, ROTA

-0.124 -0.149 -0.071 -0.434 -0.171 -0.245 -0.051 -0.857 -0.007 -0.008 -0.19 -0.441 -0.46 -0.235 0.156 -0.028 -0.144 -0.046 -0.051 0.085 -0.08 -0.033 0.01 0.009 0.011 0.015 0.019 0.019 - 0.003

Graham Net Net

-2.04 -3.73 -2.79 -3.48 -2.95 -2.57 -2.43 -3.3 -4.48 -2.71 -3.93 -3.03 -2.89 -1.51 -4.83 -1.12 1.38 0.202 2.26 1.27 4.88 -1.11 0.633 0.143 -0.347 -0.255 -0.393 -0.526 - -0.642

Working Capital

-475 M -977 M -703 M -787 M -742 M -560 M -475 M -456 M -1.15 B -428 M -383 M -30.2 M 167 M 768 M 167 M 677 M 816 M 959 M 983 M 675 M 895 M 187 M 470 M 273 M 76.5 M 63.9 M 51.3 M 47.1 M - 33.2 M

Tangible Asset Value

243 M -274 M -51.3 M -55.2 M 362 M 664 M 1.03 B 1.01 B 4.14 B 3.09 B 265 M 715 M 2.22 B 3.76 B 2.22 B 1.79 B 1.66 B 1.98 B 1.83 B 1.39 B 1.4 B 632 M 507 M 397 M 287 M 278 M 268 M 266 M - 262 M

Net Current Asset Value, NCAV

-516 M -1.02 B -771 M -874 M -793 M -573 M -580 M -597 M -1.23 B -491 M -898 M -477 M 166 M 590 M 166 M 675 M 808 M 953 M 971 M 671 M 887 M 186 M 459 M 266 M 73.1 M 61.9 M 50.7 M 44.8 M - 30.2 M

Invested Capital

260 M -237 M 7.53 M -59.9 M -18.3 M 142 M 243 M 274 M -435 M 333 M 1.1 B 1.45 B 913 M 2.39 B 913 M 1.45 B 1.6 B 1.76 B 1.45 B 1.41 B 1.35 B 588 M 838 M 554 M 271 M 259 M 248 M 251 M - 251 M

Average Receivables

143 M 132 M 96.4 M 118 M 264 M 344 M 198 M 76 M 195 M 273 M 385 M 230 M 244 M 314 M 144 M 195 M 120 M - - - - - - - - - - - - -

Average Payables

239 M 284 M 266 M 179 M 420 M 659 M 469 M 665 M 688 M 387 M 385 M 243 M 240 M 240 M 224 M 200 M 142 M 121 M 86.5 M 220 M 255 M - 16.1 M 48.2 M 66.5 M 71.1 M 76.1 M 81.7 M - -

Average Inventory

63.5 M 40.2 M 37.3 M 55.2 M 71.9 M 80.4 M 84.2 M 159 M 218 M 198 M 204 M 196 M 179 M 179 M 206 M 221 M 186 M 140 M 102 M 80.8 M 73.5 M - 68 M 74 M 74.3 M 69.1 M 66.9 M 67.7 M - -

Days Sales Outstanding

112 37.8 83.5 - 95.6 114 251 - 69.5 87.1 267 109 - 93.9 65 107 87.6 - - - - - - - - - - - - -

Days Payables Outstanding

227 106 238 76.6 176 421 796 148 850 205 317 213 55.6 1.58 K 73.1 143 47.3 141 123 22.9 1.04 K 159 - 19.6 68.2 73 85.4 91.9 - 164

Days Of Inventory On Hand

64.4 25 23.4 19.6 60 47.1 104 47.3 188 139 131 154 51.1 971 67.1 131 66.3 170 137 29.9 227 78.5 39.7 43.3 81.7 76.1 77.5 78.4 - 112

Receivables Turnover

0.803 2.38 1.08 - 0.941 0.788 0.359 - 1.29 1.03 0.337 0.827 - 0.958 1.38 0.837 1.03 - - - - - - - - - - - - -

Payables Turnover

0.397 0.846 0.378 1.17 0.513 0.214 0.113 0.609 0.106 0.439 0.284 0.423 1.62 0.057 1.23 0.627 1.9 0.64 0.731 3.93 0.086 0.565 - 4.59 1.32 1.23 1.05 0.979 - 0.548

Inventory Turnover

1.4 3.6 3.85 4.59 1.5 1.91 0.863 1.9 0.48 0.646 0.685 0.583 1.76 0.093 1.34 0.685 1.36 0.531 0.659 3.01 0.396 1.15 2.27 2.08 1.1 1.18 1.16 1.15 - 0.807

Return On Equity, ROE

-0.257 -1.16 -0.196 -1.29 -0.338 -0.411 -0.077 -1.3 -0.009 -0.009 -0.286 -0.578 -0.589 -0.251 0.201 -0.034 -0.142 -0.044 -0.055 0.09 -0.102 -0.039 0.008 0.013 0.033 0.034 0.026 0.026 - 0.004

Capex Per Share

0.0 0.0 0.0 0.001 0.0 0.02 0.012 0.05 - 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.507 0.676 0.443 0.137 0.137 0.023 0.023 0.02 0.02 0.008 0.015

All numbers in RUB currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Фармсинтез LIFE
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Фармсинтез plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
BioNTech SE BioNTech SE
BNTX
$ 97.54 -5.71 % $ 27.2 B germanyGermany
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 5.2 5.69 % $ 820 M britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Cerus Corporation Cerus Corporation
CERS
$ 2.72 33.99 % $ 518 M usaUSA
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 21.95 -2.23 % $ 3.64 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Cardiff Oncology Cardiff Oncology
CRDF
$ 1.71 -1.16 % $ 114 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
- -16.75 % $ 25.8 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
- - $ 2.18 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Editas Medicine Editas Medicine
EDIT
$ 2.9 -3.33 % $ 257 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
Edesa Biotech Edesa Biotech
EDSA
$ 17.59 -3.75 % $ 56.2 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 2.93 -8.15 % $ 4.82 M israelIsrael
Eiger BioPharmaceuticals Eiger BioPharmaceuticals
EIGR
- -9.21 % $ 2.55 M usaUSA
Eloxx Pharmaceuticals Eloxx Pharmaceuticals
ELOX
- -5.68 % $ 8.28 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
$ 0.81 3.33 % $ 27.9 M israelIsrael
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA